ORY-1001 (7), a PCPA derivative in phase II clinical trial for acute myelocytic leukemia, could inhibit TNBC cells and HER2-positive BC cells in distinct mechanisms (Figure 4) (Cuyàs et al., 2020; Wang et al., 2022). The gene discussed is ERBB2; the disease is breast cancer.